Servier (Germany)

Recent papers from Servier (Germany)

1. Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2)BMC Cancer · 2026
2. Trustworthy AutoML indicators for climate-smart agriculture: A sustainability-governance framework for decision supportEnvironmental and Sustainability Indicators · 2026
3. Exploratory Analyses from the Phase Three INDIGO Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With Vorasidenib (S28.002)Neurology · 2026
4. Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programsBlood · 2026
5. Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study.Journal of Clinical Oncology · 2026
6. IDH1 and IDH2 mutated myeloid neoplasms: mutational pattern, clonal hierarchy and the role in AML transformationBlood Advances · 2026
7. Js05.6.a Exploratory Analyses From Phase 3 Indigo Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With VorasidenibNeuro-Oncology · 2025
8. Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in GermanyJournal of Neuro-Oncology · 2025
9. Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension studyEuropean Child & Adolescent Psychiatry · 2024
10. Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trialBMC Cancer · 2024
11. Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case ReportsCase Reports in Oncology · 2024
12. Unresectable biliary tract cancer: Current and future systemic therapyEuropean Journal of Cancer · 2024
13. Liquid biopsy into the clinics: Current evidence and future perspectivesThe Journal of Liquid Biopsy · 2024
14. Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/TipiracilChemotherapy · 2023
15. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in GermanyInternational Journal of Cancer · 2023
16. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)BMC Cancer · 2023
17. Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trialESMO Open · 2022
18. Effectiveness and Impact on Adherence of a New Fixed-Dose Combination of Ivabradine and Metoprolol in a Wide Range of Stable Angina Patients in Real-Life PracticeCardiology and Therapy · 2019
19. Utility and quality-adjusted life-years in coronary artery diseaseMedicine · 2017
20. Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical PracticeCardiology and Therapy · 2017